Utility of Daratumumab as Bridging Therapy in De Novo T-Cell Acute Lymphoblastic Lymphoma

Research output: Contribution to journal › Letter › peer-review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{5d5bbb60db5847cea8a29d242e650e0c,

title = "Utility of Daratumumab as Bridging Therapy in De Novo T-Cell Acute Lymphoblastic Lymphoma",

author = "Holzmann, \{Jonathan J.\} and Kotecha, \{Rishi S.\}",

year = "2025",

month = mar,

doi = "10.1002/pbc.31526",

language = "English",

volume = "72",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "John Wiley \& Sons",

number = "3",

}

TY - JOUR

T1 - Utility of Daratumumab as Bridging Therapy in De Novo T-Cell Acute Lymphoblastic Lymphoma

AU - Holzmann, Jonathan J.

AU - Kotecha, Rishi S.

PY - 2025/3

Y1 - 2025/3

UR - https://www.scopus.com/pages/publications/85214387687

U2 - 10.1002/pbc.31526

DO - 10.1002/pbc.31526

M3 - Letter

C2 - 39762504

AN - SCOPUS:85214387687

SN - 1545-5009

VL - 72

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 3

M1 - e31526

ER -